CEL-SCI Corporation (CVM) Income Statement
CVM FY2025 at a glance
Fiscal year ended September 30, 2025 · U.S. dollarsCVM revenue and net income
CVM profit margins
CVM growth rates
to FY2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
CVM quarterly EPS vs estimates
CEL-SCI beat the analyst EPS estimate in 1 of the last 4 quarters.
CVM income statement
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $558,664 | $462,754 | $476,556 | $69,020 | $285,055 |
| Cost of revenue | $15.9M | $4.0M | $22.5M | $3.9M | $499,000 | $17.8M | $12,659 | $10,914 | $633,000 | $17,445 |
| Gross profit | −$15.9M | −$4.0M | −$22.5M | −$3.9M | −$499,000 | −$17.3M | $450,095 | $465,642 | −$563,980 | $267,610 |
| Research & development | $15.9M | $18.2M | $22.5M | $25.4M | $23.1M | $17.8M | $12.7M | $9.4M | $15.6M | $19.4M |
| Sales, general & admin | $8.9M | $7.8M | $8.6M | $10.7M | $13.1M | $11.7M | $8.0M | $7.8M | $5.8M | $6.5M |
| Total operating expenses | $8.9M | $22.4M | $9.0M | $36.1M | $36.2M | $11.7M | $20.2M | $16.8M | $21.3M | $25.6M |
| Operating income | −$24.8M | −$26.4M | −$31.5M | −$36.1M | −$36.2M | −$29.0M | −$20.2M | −$16.8M | −$21.3M | −$25.6M |
| Interest income | — | — | $675,420 | $714,240 | $1.8M | $1.4M | $2.6M | $15.1M | $7.0M | $12.1M |
| Interest expense | $648,944 | $745,673 | $675,416 | $1.1M | $1.1M | $1.0M | $1.8M | $0 | $4.0M | $0 |
| Income before taxes | −$25.4M | −$26.9M | −$32.4M | −$36.7M | −$36.4M | −$30.3M | −$22.1M | −$31.8M | −$14.4M | −$11.5M |
| Income taxes | — | — | $632,603 | $1.6M | $2.8M | $2.0M | $2.6M | −$15.1M | −$7.0M | −$14.1M |
| Net income | −$25.4M | −$26.9M | −$32.4M | −$36.7M | −$36.4M | −$30.3M | −$24.7M | −$31.8M | −$14.4M | −$11.5M |
| EBITDA | −$20.9M | −$22.2M | −$27.5M | −$31.8M | −$33.0M | −$26.8M | −$19.7M | −$16.1M | −$9.7M | −$9.1M |
| EPS (diluted) | −$7.25 | −$19.50 | −$16.96 | −$14.21 | −$20.91 | −$19.96 | −$15.18 | −$1.87 | −$2.04 | −$2.30 |
| Gross margin | — | — | — | — | — | −3,093.4% | 97.3% | 97.7% | −817.1% | 93.9% |
| Operating margin | — | — | — | — | — | −5,188.3% | −4,364.1% | −3,519.5% | −30,916.1% | −8,964.3% |
| Net margin | — | — | — | — | — | −5,419.5% | −5,336.0% | −6,680.7% | −20,810.3% | −4,022.6% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $6.0M | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $946,370 | $956,401 | $3.7M | $960,850 | $959,009 | $4.0M | $995,192 | — | $983,208 | $988,762 | $1.0M | $998,653 |
| Gross profit | −$946,370 | −$956,401 | −$3.7M | −$960,850 | −$959,009 | −$4.0M | −$995,192 | — | −$983,208 | −$988,762 | −$1.0M | −$998,653 |
| Research & development | $3.6M | $3.8M | $3.7M | $3.7M | $3.7M | $4.0M | $4.4M | $4.5M | $4.7M | $4.6M | $4.4M | $5.3M |
| Sales, general & admin | $1.9M | $1.6M | $1.7M | $2.3M | $1.7M | $2.4M | $2.5M | $1.6M | $2.0M | $2.4M | $2.1M | $2.2M |
| Total operating expenses | $4.6M | $4.4M | $1.7M | $5.1M | $4.5M | $2.4M | $5.9M | $6.1M | $6.7M | $6.1M | $6.5M | $6.5M |
| Operating income | −$5.6M | −$5.3M | −$5.4M | −$6.0M | −$5.5M | −$6.4M | −$6.9M | −$6.1M | −$6.7M | −$7.1M | −$6.5M | −$7.5M |
| Interest income | — | — | $87,790 | $128,500 | $172,050 | $178,290 | $170,100 | $174,570 | — | — | — | — |
| Interest expense | $110,240 | $117,485 | $87,789 | $128,505 | $172,050 | $178,286 | $170,103 | $174,571 | $190,705 | $182,701 | $197,696 | $181,894 |
| Income before taxes | −$5.7M | −$5.5M | −$5.5M | −$6.1M | −$5.7M | −$6.6M | −$7.1M | −$6.1M | −$6.9M | −$7.2M | −$6.7M | −$7.6M |
| Income taxes | — | — | — | — | — | — | −$171,753 | — | $2 | −$2 | $171,755 | $200,606 |
| Net income | −$5.7M | −$5.5M | −$5.5M | −$6.1M | −$5.7M | −$6.6M | −$7.1M | −$6.1M | −$6.9M | −$7.2M | −$6.7M | −$7.6M |
| EBITDA | −$4.6M | −$4.4M | −$4.4M | −$5.1M | −$4.5M | −$5.4M | −$5.9M | — | −$5.7M | −$6.1M | −$5.5M | −$6.5M |
| EPS (diluted) | −$0.47 | — | −$0.68 | −$0.86 | −$1.36 | −$2.33 | −$2.70 | −$2.70 | −$4.20 | −$8.40 | −$4.20 | −$0.16 |
| Gross margin | — | — | — | — | — | — | −16.7% | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | −115.8% | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | −118.8% | — | — | — | — | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in CVM's financial statements (latest annual report filed December 29, 2025); data from EODHD. Sales, general & administrative expenses include sales and marketing.
CVM financial results
CEL-SCI reported no revenue in fiscal year 2025 (ended September 30, 2025). It had a net loss of $25.4 million. Diluted earnings per share came to −$7.25.
See the CVM stock overview for the latest quote and news, or the CVM chart for price history and technical indicators.
CVM income statement FAQ
Does CEL-SCI have revenue?
CEL-SCI reported no revenue for fiscal year 2025, which ended on September 30, 2025.
Is CEL-SCI profitable?
No. CEL-SCI reported a net loss of $25.4 million in fiscal 2025.
How much does CEL-SCI spend on research and development?
CEL-SCI spent $15.9 million on research and development in fiscal 2025.
What are CEL-SCI's earnings per share?
CEL-SCI earned $-7.25 per diluted share in fiscal 2025, compared with $-19.50 a year earlier.
When does CEL-SCI's fiscal year end?
CEL-SCI's fiscal year ends in September. The latest annual report covers the year ended September 30, 2025 and was filed on December 29, 2025.